Study demonstrates dual-functional nanoparticles improve antifibrotic treatment in pulmonary fibrosis via mesenchymal stem cells, suggesting enhanced therapeutic outcomes.
Pulmonary fibrosis is a debilitating lung disease for which effective therapies remain limited. In this study, we developed a mesenchymal stem cell (MSC)-based delivery system incorporating PDA@Au/CeO₂ nanoparticles (MSCs-PDA@Au/CeO₂/NT) for targeted antifibrotic therapy and imaging guidance. PDA@Au/CeO₂ nanoparticles showed excellent biocompatibility, efficient MSC uptake, and superior CT imaging performance. In TGF-β1-induced fibroblast models, the composite system markedly inhibited myofibroblast differentiation, suppressed ROS accumulation, and selectively induced apoptosis of aberrantly activated fibroblasts while preserving MSC viability. In bleomycin-induced pulmonary fibrosis mice, MSCs-PDA@Au/CeO₂/NT significantly improved lung architecture and function, decreased collagen deposition, and modulated the immune microenvironment by downregulating fibrosis-related signaling pathways. Biosafety assessments confirmed no significant systemic toxicity. This study demonstrates a safe and effective nanomaterial-assisted stem cell strategy for pulmonary fibrosis treatment and potential clinical translation.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: